Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tarextumab

- PMLiVE

Monitoring app boosts survival in lung cancer patients

Results of prototype Moovcare remote monitoring device released at ASCO 2016

- PMLiVE

Trial of AbbVie’s Rova-T disappoints at ASCO

But company says the modest trial data is “a good early sign” for lung cancer drug

Daiichi Sankyo logo

Daiichi pulls study of patritumab in lung cancer

HER3 inhibitor candidate showed no evidence of efficacy in trial analysis

National Institute for Health and Care Excellence NICE logo

NICE rejects Opdivo for lung cancer once again

Says PD-1 inhibitor is too expensive to be used routinely

- PMLiVE

FDA approves expanded indication for Gilotrif

US body gives Boehringer Ingelheim’s oral lung cancer treatment the nod

- PMLiVE

FDA panel says no to quick approval of Clovis’ rociletinib

Recommends waiting for phase III trial results after "serious" safety concerns

EU flag

Boehringer’s Giotrif wins new NSCLC licence in Europe

Can now be marketed for advanced squamous cell carcinoma of the lung

- PMLiVE

AZ cancer immunotherapy combo impresses in lung cancer trial

Durvalumab and tremelimumab combination show 'encouraging' efficacy signs

- PMLiVE

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa gets FDA OK

Wins accelerated US approval for non-small cell lung cancer

- PMLiVE

Boehringer’s coughing beat box drives its message home

Throat hacking performance raises awareness of lung cancer symptom

- PMLiVE

UK patients get early access to AZ’s lung cancer drug Tagrisso

The treatment is the fourth made available under the EAMS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links